Sign In
NewsRadar

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.

   


Luminex and Exiqon Announce Development and Commercialization Agreement
New microRNA products will be developed by Exiqon for the Luminex Bioscience Group.


AUSTIN, Texas and COPENHAGEN, Denmark (September 19, 2006)― Luminex® Corporation (NASDAQ: LMNX), a leading multiplex solution developer, and Exiqon A/S, a leading supplier of high-value gene expression analysis products, announced today the signing of an agreement to co-develop and commercialize microRNA products. Exiqon will develop and manufacture microRNA products on behalf of the Luminex Bioscience Group (LBG) based on Luminex’s xMAP® technology and Exiqon’s Locked Nucleic Acid (LNA™) technology. Combining the strengths and unique advantages of both companies’ core technologies will create a line of microRNA products that are comprehensive, highly specific and easy to use.

Patrick J. Balthrop, president and chief executive officer of Luminex, commented, “This development and commercialization agreement with Exiqon demonstrates Luminex’s commitment to launch new products that meet the needs of a broad spectrum of end-users. In the coming months we expect to serve our customers with a superior product solution in a high growth market as LBG provides these microRNA products through our partner base. We anticipate this and other future LBG applications will significantly enhance our partners’ leadership in multiplexed life science research and diagnostics.”

Lars Kongsbak, president and chief executive officer of Exiqon, added, “Combining the ease-of-use and high multiplexing capacity of the Luminex xMAP platform with the high sensitivity and specificity of our LNA probes will result in a unique product offering. Luminex xMAP instruments hold a significant share of detection platforms in the life sciences industry in both the research and clinical settings. This collaboration will ensure our highly specific microRNA detection chemistries are broadly available to this market segment, which is an important strategic accomplishment for Exiqon.”


About microRNAs and LNA™
microRNAs (miRNAs) are a class of regulatory RNA molecules with widespread effects on gene regulation. Although recently identified as a new class of molecules, initial studies indicate that miRNAs may regulate as much as one third of all genes in the genome. Thus miRNAs comprise an up-until-now hidden level of gene regulation.

Interestingly, miRNAs have already been found to have important roles in several types of cancers and in processes involved in cellular differentiation. In the cell, miRNAs are found in the form of single-stranded RNA molecules, which are typically 20-25 nucleotides long in their active form. LNAs (Locked nucleic acids) are a class of nucleotide analogue that binds very strongly to RNA and DNA targets. By including LNAs in detection probes, it is possible to design very specific high-affinity detection assays for small RNA targets like miRNAs, which otherwise would not be possible using standard DNA-based detection probes.


About Exiqon
Exiqon is a leading supplier of high-value gene expression analysis products for the life sciences, research and drug discovery industries. Exiqon’s rapidly growing product offerings integrate innovative chemistries with web-based software tools to help scientists achieve rapid and reliable results. Exiqon markets its products directly on www.exiqon.com or through distributors in the EU and Asia, as well as through its new, dedicated US sales force. Exiqon is located in the Medicon Valley area of Copenhagen, Denmark and in Boston, USA. Please visit our web-site at www.exiqon.com.


About Luminex
Luminex Corporation develops, manufactures and markets proprietary biological testing technologies with applications throughout the life sciences industry. The Company’s xMAP system is an open-architecture, multi-analyte technology platform that delivers fast, accurate and cost-effective bioassay results to markets as diverse as pharmaceutical drug discovery, clinical diagnostics and biomedical research, including the genomics and proteomics research markets. The Company's xMAP technolog


Publisher Contact Information:

Exiqon A/S
+45 45 65 04 50
lk@exiqon.com

Company profile of Exiqon A/S
Past press releases of Exiqon A/S.

Data


26,032
Tech investments
From our Online Data Service
16,834
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
Aug 25€26.0MPayment software
Aug 25€5.1MInternet services
Aug 25€36.0MPayment software
Aug 24€23.0MOther Biotechnology & Healthcare
Aug 23N/AImaging
Aug 23€1.1MSoftware development
Aug 22€1.8MEnergy related

For information on Europe's most extensive database on technology funding click here!

Events



Press Releases


May 28
Identiq
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
Nethone
nethone raised over $1 million from innovation nest

Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase

Jan 2
Urban Jungle
urban jungle raises £1m in seed funding to build tech-enabled home ...





About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.